Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "HPV Vaccination: Current Situation and Future Goals"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: 31 July 2023 | Viewed by 5939
Special Issue Editors
Interests: HPV epidemiology; HPV vaccination; cervical cancer screening; cervical cancer prevention
Special Issue Information
More than 40 years have passed since in the 1980s Harald Zur Hausen, a German virologist, isolated Human papillomavirus (HPV) strains from cervical cancer tissue. His studies confirmed the theory that HPV is linked to cervical cancer development and acts as one of the main causative agents. In 1986 Zur Hausen proposed the idea of the HPV vaccine as a cancer prevention method. After years of experiments, the knowledge that persistent high-risk HPV infection is causally associated with cervical cancer has resulted in the development of prophylactic vaccines to prevent HPV infection. The first HPV vaccine was developed at the University of Queensland in Australia by Professors Ian Frazer and Jian Zhou. The vaccine was approved in 2006-2007 in more than 80 countries worldwide. HPV vaccines are currently among the most effective prophylactic vaccines ever created and made available, and proven to be effective in reducing HPV-related diseases rates. HPV vaccination programs have been developed and successfully implemented in many high-income countries and have led to a decline in cervical cancer incidence rates. However, the situation in low-income countries remains deplorable – HPV-related cancers still display a high incidence, including cervical cancer, which remains the leading cause of cancer-related death in women of the developing world. Although the HPV vaccination is successfully implemented in many countries worldwide, there are still multiple issues related to its dissemination and acceptance. HPV vaccination access, coverage, attitudes, and acceptance are not the same in different parts of the world.
Thus, to achieve a more extensive understanding of current scientific knowledge and trends in HPV vaccines implementation, this Special Issue is focused on the recent updates in this field. Based on your extensive knowledge and experience, we invite you to contribute with an original report, original observation, or review, to highlight the current situation related to (i) HPV vaccination coverage, (ii) attitudes towards HPV vaccination, (iii) HPV vaccination knowledge and awareness, (iv) HPV vaccines acceptance, (v) factors associated with the implementation of HPV vaccination programs locally and worldwide, (vi) effective instruments/interventions to improve the HPV vaccination public acceptance, (vii) impact of the COVID-19 pandemic on HPV vaccination.
Dr. Gulzhanat Aimagambetova
Dr. Azliyati Azizan
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- HPV infection
- HPV vaccination
- HPV prevention
- cervical cancer prevention
- HPV vaccine acceptance